четверг, 22 декабря 2016 г.

Bad News Bashes Biotech Investors... Again

Bad News Bashes Biotech Investors... Again


Alexion's top brass has hit the exits amid an investigation into sales practices, and Ophthotech's future is in jeopardy following a high-profile phase 3 failure. At Alexion Pharmaceuticals, the sudden departure of top executives in the midst of an ongoing internal investigation caused its shares to tumble 13%.



from Biotech News